CVS Caremark (CVS) Tops Q2 EPS by 1c; Narrows FY11 Outlook
Tweet
Share
E-mail
Get Alerts CVS Hot Sheet
Price: $101.30 +3.03%
Revenue Growth %: +1.2%
Financial Fact:
Weighted average basic common shares outstanding (in shares): 1.07B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +1.2%
Financial Fact:
Weighted average basic common shares outstanding (in shares): 1.07B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
CVS Caremark (NYSE: CVS) reported Q2 EPS of $0.65, $0.01 better than the analyst estimate of $0.64. Revenue for the quarter came in at $26.6 billion versus the consensus estimate of $26.76 billion.
Sees FY2011 EPS of $2.75-$2.81, versus prior guidance of $2.72-$2.82 and the consensus of $2.78.
UPDATE - from its Q2 conference call: sees Q3 adj-EPS of 66-68c, vs. the consensus of 68c.
Sees FY2011 EPS of $2.75-$2.81, versus prior guidance of $2.72-$2.82 and the consensus of $2.78.
UPDATE - from its Q2 conference call: sees Q3 adj-EPS of 66-68c, vs. the consensus of 68c.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CVS Health (CVS) PT Raised to $110 at BofA Securities
- PowerFleet, Inc. (AIOT) Misses Q1 EPS by 2c ; Offers Guidance
- CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
